{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:40:05Z","timestamp":1762674005450,"version":"3.40.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T00:00:00Z","timestamp":1415059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>\u2003<\/jats:title><jats:p>Postmenopausal osteoporosis is a chronic disease wherein increased bone remodeling reduces bone mass and bone strength. Antiresorptive agents including bisphosphonates are commonly used to mitigate bone loss and fracture risk. Osteoclast inhibition via denosumab (DMAb), a RANKL inhibitor, is a newer approach for reducing fracture risk in patients at increased risk for fracture. The safety of transitioning from bisphosphonate therapy (alendronate; ALN) to DMAb was examined in mature ovariectomized (OVX) cynomolgus monkeys (cynos). One day after OVX, cynos (7\u201310\/group) were treated with vehicle (VEH, s.c.), ALN (50\u2009\u03bcg\/kg, i.v., twice monthly) or DMAb (25\u2009mg\/kg\/month,\u2009s.c.) for 12 months. Other animals received VEH or ALN for 6 months and then transitioned to 6 months of DMAb. DMAb caused significantly greater reductions in serum CTx than ALN, and transition from ALN to DMAb caused further reductions relative to continued ALN. DMAb and ALN decreased serum calcium (Ca), and transition from ALN to DMAb resulted in a lesser decline in Ca relative to DMAb or to VEH-DMAb transition. Bone histomorphometry indicated significantly reduced trabecular and cortical remodeling with DMAb or ALN. Compared with ALN, DMAb caused greater reductions in osteoclast surface, eroded surface, cortical porosity and fluorochrome labeling, and transition from ALN to DMAb reduced these parameters relative to continued ALN. Bone mineral density increased in all active treatment groups relative to VEH controls. Destructive biomechanical testing revealed significantly greater vertebral strength in all three groups receiving DMAb, including those receiving DMAb after ALN, relative to VEH controls. Bone mass and strength remained highly correlated in all groups at all tested skeletal sites, consistent with normal bone quality. These data indicate that cynos transitioned from ALN to DMAb exhibited reduced bone resorption and cortical porosity, and increased BMD and bone strength, without deleterious effects on Ca homeostasis or bone quality. \u00a9 2014 American Society for Bone and Mineral Research.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jbmr.2401","type":"journal-article","created":{"date-parts":[[2014,11,4]],"date-time":"2014-11-04T23:12:10Z","timestamp":1415142730000},"page":"657-669","source":"Crossref","is-referenced-by-count":38,"title":["Effects of Denosumab, Alendronate, or Denosumab Following Alendronate on Bone Turnover, Calcium Homeostasis, Bone Mass and Bone Strength in Ovariectomized Cynomolgus Monkeys"],"prefix":"10.1093","volume":"30","author":[{"given":"Paul J","family":"Kostenuik","sequence":"first","affiliation":[{"name":"Metabolic Disorders ResearchAmgen Inc.Thousand OaksCA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan Y","family":"Smith","sequence":"additional","affiliation":[{"name":"Musculoskeletal ResearchCharles River LaboratoriesPreclinical Services MontrealQuebecCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Samadfam","sequence":"additional","affiliation":[{"name":"Musculoskeletal ResearchCharles River LaboratoriesPreclinical Services MontrealQuebecCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacquelin","family":"Jolette","sequence":"additional","affiliation":[{"name":"Musculoskeletal ResearchCharles River LaboratoriesPreclinical Services MontrealQuebecCanada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[{"name":"BiostatisticsAmgen Inc.Thousand OaksCA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S","family":"Ominsky","sequence":"additional","affiliation":[{"name":"Metabolic Disorders ResearchAmgen Inc.Thousand OaksCA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,11,4]]},"reference":[{"key":"2024020319165768300_jbmr2401-bib-0001","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020319165768300_jbmr2401-bib-0002","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med."},{"key":"2024020319165768300_jbmr2401-bib-0003","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0004","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2011.04.001","article-title":"Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys","volume":"49","author":"Ominsky","year":"2011","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0006","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bone.2011.03.769","article-title":"Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"49","author":"Kostenuik","year":"2011","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0007","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S8756-3282(02)00923-7","article-title":"Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomogus monkeys","volume":"32","author":"Smith","year":"2003","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0008","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1402.089","article-title":"Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy","volume":"1117","author":"Russell","year":"2007","journal-title":"Ann NY Acad Sci."},{"key":"2024020319165768300_jbmr2401-bib-0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1006\/bbrc.1999.0224","article-title":"Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase\/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo","volume":"255","author":"Van Beek","year":"1999","journal-title":"Biochem Biophys Res Commun."},{"key":"2024020319165768300_jbmr2401-bib-0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0011","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol."},{"key":"2024020319165768300_jbmr2401-bib-0012","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0013","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2013","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","article-title":"Differing effects of denosumab and alendronate on cortical and trabecular bone","volume":"59","author":"Zebaze","year":"2014","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0015","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1210\/jc.2013-4175","article-title":"Fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT)","volume":"99","author":"Nakamura","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020319165768300_jbmr2401-bib-0016","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0017","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jbmr.1854","article-title":"Goal-directed treatment of osteoporosis","volume":"28","author":"Cummings","year":"2013","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0018","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0019","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr Pract."},{"key":"2024020319165768300_jbmr2401-bib-0020"},{"key":"2024020319165768300_jbmr2401-bib-0021","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1172\/JCI116872","article-title":"The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates","volume":"92","author":"Balena","year":"1993","journal-title":"J Clin Invest."},{"key":"2024020319165768300_jbmr2401-bib-0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00223-009-9279-x","article-title":"Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys","volume":"85","author":"Stroup","year":"2009","journal-title":"Calcif Tissue Int."},{"key":"2024020319165768300_jbmr2401-bib-0023","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: standardization of nomenclature, symbols, and units","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0024","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1359\/jbmr.070720","article-title":"Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment","volume":"22","author":"Allen","year":"2007","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0025","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","article-title":"Identification of the risk factors associated with hypocalcemia induced by denosumab","volume":"36","author":"Okada","year":"2013","journal-title":"Biol Pharm Bull."},{"key":"2024020319165768300_jbmr2401-bib-0026"},{"key":"2024020319165768300_jbmr2401-bib-0027","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02509543","article-title":"Effects of low-dose long-term sodium fluoride preventive treatment on rat bone mass and biomechanical properties","volume":"58","author":"Jiang","year":"1996","journal-title":"Calcif Tissue Int."},{"key":"2024020319165768300_jbmr2401-bib-0028","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00198-007-0451-8","article-title":"Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs","volume":"19","author":"Allen","year":"2008","journal-title":"Osteoporos Int."},{"key":"2024020319165768300_jbmr2401-bib-0029","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1359\/jbmr.2000.15.4.613","article-title":"Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib","volume":"15","author":"Mashiba","year":"2000","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0030","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-008-9131-8","article-title":"Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment","volume":"82","author":"Allen","year":"2008","journal-title":"Calcif Tissue Int."},{"key":"2024020319165768300_jbmr2401-bib-0031","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/B978-0-12-415853-5.00037-6","volume-title":"Osteoporosis","author":"Kostenuik","year":"2013"},{"key":"2024020319165768300_jbmr2401-bib-0032","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S8756-3282(01)00575-0","article-title":"Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures","volume":"29","author":"Mashiba","year":"2001","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0033","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1359\/jbmr.090215","article-title":"One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density and strength","volume":"24","author":"Ominsky","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020319165768300_jbmr2401-bib-0034","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S8756-3282(01)00615-9","article-title":"Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis","volume":"29","author":"Halazy-Nagy","year":"2001","journal-title":"Bone."},{"key":"2024020319165768300_jbmr2401-bib-0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol."},{"key":"2024020319165768300_jbmr2401-bib-0036","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2353\/ajpath.2009.081026","article-title":"Osteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH\/PTHrP receptor","volume":"174","author":"Ohishi","year":"2009","journal-title":"Am J Pathol."},{"key":"2024020319165768300_jbmr2401-bib-0037","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0090-9556(25)08706-9","article-title":"Effects of dose, sex and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metabol Dispos."},{"key":"2024020319165768300_jbmr2401-bib-0038","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2401","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/4\/657\/56567923\/jbmr2401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/30\/4\/657\/56567923\/jbmr2401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:20:23Z","timestamp":1747146023000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/30\/4\/657-669\/7599221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2014,11,4]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2401","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"type":"print","value":"0884-0431"},{"type":"electronic","value":"1523-4681"}],"subject":[],"published-other":{"date-parts":[[2015,4,1]]},"published":{"date-parts":[[2014,11,4]]}}}